Global Allogeneic Stem Cell Transplantation Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Allogeneic Stem Cell Transplantation Market Insights, Forecast to 2034
Market Analysis and InsightsGlobal Allogeneic Stem Cell Transplantation Market
Global Allogeneic Stem Cell Transplantation market is expected to reach to US$ 1060 million in 2023, with a positive growth of %, compared with US$ 1000 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Allogeneic Stem Cell Transplantation industry is evaluated to reach US$ 1503.6 million in 2033. The CAGR will be 6.0% during 2023 to 2033.
Globally, Allogeneic Stem Cell Transplantation key companies include Mesoblast Limited, Gamida Cell Ltd., Novartis International AG, Cellectis SA, Magenta Therapeutics Inc., Fate Therapeutics Inc., Cynata Therapeutics Limited, Kiadis Pharma N.V and Takeda Pharmaceutical Company Limited, etc. Mesoblast Limited, Gamida Cell Ltd., Novartis International AG are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Allogeneic Stem Cell Transplantation were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Allogeneic Stem Cell Transplantation market and estimated to attract more attentions from industry insiders and investors.
Allogeneic Stem Cell Transplantation can be divided into Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant and Donor Lymphocyte Infusion, etc. Unmodified Stem Cell Transplant is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Allogeneic Stem Cell Transplantation is widely used in various fields, such as Hospital, Ambulatory Surgical Center and Others,, etc. Hospital provides greatest supports to the Allogeneic Stem Cell Transplantation industry development. In 2022, global % revenue of Allogeneic Stem Cell Transplantation went into Hospital filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Allogeneic Stem Cell Transplantation market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Allogeneic Stem Cell Transplantation market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Mesoblast Limited
Gamida Cell Ltd.
Novartis International AG
Cellectis SA
Magenta Therapeutics Inc.
Fate Therapeutics Inc.
Cynata Therapeutics Limited
Kiadis Pharma N.V
Takeda Pharmaceutical Company Limited
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Celularity Inc.
Lineage Cell Therapeutics Inc.
Nohla Therapeutics Inc.
Orchard Therapeutics Plc
Segment by Type
Unmodified Stem Cell Transplant
T-cell Depleted Transplant
Cord Blood Transplant
Donor Lymphocyte Infusion
Hospital
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Allogeneic Stem Cell Transplantation introduction, etc. Allogeneic Stem Cell Transplantation Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Allogeneic Stem Cell Transplantation
Chapter 13Methodology and Data Sources adopted by MRAResearch
Global Allogeneic Stem Cell Transplantation market is expected to reach to US$ 1060 million in 2023, with a positive growth of %, compared with US$ 1000 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Allogeneic Stem Cell Transplantation industry is evaluated to reach US$ 1503.6 million in 2033. The CAGR will be 6.0% during 2023 to 2033.
Globally, Allogeneic Stem Cell Transplantation key companies include Mesoblast Limited, Gamida Cell Ltd., Novartis International AG, Cellectis SA, Magenta Therapeutics Inc., Fate Therapeutics Inc., Cynata Therapeutics Limited, Kiadis Pharma N.V and Takeda Pharmaceutical Company Limited, etc. Mesoblast Limited, Gamida Cell Ltd., Novartis International AG are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Allogeneic Stem Cell Transplantation were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Allogeneic Stem Cell Transplantation market and estimated to attract more attentions from industry insiders and investors.
Allogeneic Stem Cell Transplantation can be divided into Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant and Donor Lymphocyte Infusion, etc. Unmodified Stem Cell Transplant is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Allogeneic Stem Cell Transplantation is widely used in various fields, such as Hospital, Ambulatory Surgical Center and Others,, etc. Hospital provides greatest supports to the Allogeneic Stem Cell Transplantation industry development. In 2022, global % revenue of Allogeneic Stem Cell Transplantation went into Hospital filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Allogeneic Stem Cell Transplantation market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Allogeneic Stem Cell Transplantation market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Mesoblast Limited
Gamida Cell Ltd.
Novartis International AG
Cellectis SA
Magenta Therapeutics Inc.
Fate Therapeutics Inc.
Cynata Therapeutics Limited
Kiadis Pharma N.V
Takeda Pharmaceutical Company Limited
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Celularity Inc.
Lineage Cell Therapeutics Inc.
Nohla Therapeutics Inc.
Orchard Therapeutics Plc
Segment by Type
Unmodified Stem Cell Transplant
T-cell Depleted Transplant
Cord Blood Transplant
Donor Lymphocyte Infusion
Segment by Application
Hospital
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Allogeneic Stem Cell Transplantation introduction, etc. Allogeneic Stem Cell Transplantation Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Allogeneic Stem Cell Transplantation
Chapter 13Methodology and Data Sources adopted by MRAResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices